TVTX
Travere Therapeutics, Inc.
8.65
USD
This page is just a preview of the data found in TrendSpider’s full version
Travere Therapeutics, Inc. stock is up 55.02% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45% of the previous 20 December’s closed higher than November. In the last 5 Unusual Options Trades, there were 4 PUTs, 1 CALL. 67% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 16 Oct 16:08 | 20 Oct, 2023 | 10.00 | 563 | ||
| 15 Nov 18:45 | 21 Jun, 2024 | 7.50 | 3617 | ||
| 15 Nov 19:25 | 21 Jun, 2024 | 7.50 | 3617 | ||
| 01 Dec 20:56 | 21 Jun, 2024 | 7.50 | 5634 | ||
| 08 Dec 17:21 | 15 Mar, 2024 | 7.50 | 53 |
Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.
